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Sciences, School of Pharmacy, University of Maryland, Baltimore, MarylandABSTRACT Using implicit solvent molecular dynamics and replica exchange simulations, we study the impact of ibuprofen on
the growth of wild-type Ab ﬁbrils. We show that binding of ibuprofen to Ab destabilizes the interactions between incoming
peptides and the ﬁbril. As a result, ibuprofen interference modiﬁes the free energy landscape of ﬁbril growth and reduces the
free energy gain of Ab peptide binding to the ﬁbril byx2.5 RT at 360 K. Furthermore, ibuprofen interactions shift the thermody-
namic equilibrium from ﬁbril-like locked states to disordered docked states. Ibuprofen’s anti-aggregation effect is explained by its
competition with incoming Ab peptides for the same binding site located on the ﬁbril edge. Although ibuprofen impedes ﬁbril
growth, it does not signiﬁcantly change the mechanism of ﬁbril elongation or the structure of Ab peptides bound to the ﬁbril.INTRODUCTIONA class of diseases, including Alzheimer’s, Parkinson’s, type
II diabetes, and Creutzfeldt-Jakob disease, are linked to aber-
rant aggregation of polypeptide chains (1). Aggregation
pathway proceeds through cascading structural transitions
initiated by oligomerization of monomeric chains, which
eventually result in the appearance of amyloid fibrils (2).
Recent experimental findings suggested that, rather than
fibrils, oligomers that are as small as dimers are the primary
cytotoxic species (3,4). Irrespective of their cytotoxicity,
fibrils are the reservoirs of monomers and, consequently,
participate in the equilibrium recycling of polypeptides
through different aggregated species (5–7). From the
structural perspective, amyloid fibrils display several unique
properties:
1. Small sequence homology is observed among amyloido-
genic polypeptides;
2. Fibril internal architecture is based on the b-sheet struc-
ture (8–12); and
3. Amyloid fibrils are highly resistant to dissociation (13).
Ab peptides are 39–42 residue amyloidogenic fragments
of membrane precursor protein, which are produced in the
course of cellular proteolysis (14) (Fig. 1 a). Experimental
observations suggest that amyloidogenesis of Ab peptides
is a seminal event in Alzheimer’s disease (AD) (15). Conse-
quently, prevention of Ab aggregation is a viable therapeutic
strategy, which could involve the use of small molecular
ligands to interfere with amyloid assembly. One such
candidate ligand is the nonsteroidal anti-inflammatory drug
ibuprofen (16) (Fig. 1 b). Mouse models have shown that
it can reduce the extent of Ab deposition and alleviate
memory deficits (17,18). Ibuprofen also decreases the load
of Ab oligomers in mice brains (18). Prophylactic long-Submitted December 18, 2009, and accepted for publication February 16,
2010.
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0006-3495/10/06/2662/9 $2.00term intake of ibuprofen appears to reduce the risk of AD
in humans (19), but its clinical use is hampered by side
effects.
Although ibuprofen may play different therapeutic roles in
AD, in vitro experiments support direct anti-aggregation
effect produced by this ligand. It has been shown that
coincubation of ibuprofen with Ab reduces the accumula-
tion of fibrils (20,21). Ibuprofen also dissociates, at least
partially, preformed Ab fibrils (21). However, little is known
about Ab-ibuprofen interactions on a molecular level. For
example:
1. Does ibuprofen decrease the thermodynamic stability of
fibrils?
2. Is the anti-aggregation effect due to the competition of
ibuprofen and Ab peptides for the same binding sites in
Ab fibril?
3. Does ibuprofen binding change the fibril growth mecha-
nism and/or the Ab peptide structure?
These questions can be investigated by molecular dynamics
(MD) simulations (22), which have been used to explore
the pathways of amyloid assembly (23–26), the conforma-
tional ensembles of amyloidogenic peptides (27–29), and
the energetics of fibril structures (30,31). More recently, MD
simulations probed binding of small ligands to amyloido-
genic peptides (32–35).
In this article, to address the questions posed above, we use
the atomistic implicit solvent model and replica exchange
molecular dynamics (REMD) (36). By using this approach,
we have already shown that, consistent with the experiments
(37,38), equilibrium fibril growth involves two thermodynam-
ically distinct transitions—docking and locking (26). Docking
occurs upon binding disordered Ab monomers to the fibril
without their integration into the fibril structure. During
locking, incoming peptides adopt a fibril-like state through
activated structural transition. Our preliminary studies have
also examined the binding of ibuprofen to Ab monomers
and, separately, to Ab fibrils (34). Here, through exhaustivedoi: 10.1016/j.bpj.2010.02.031
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FIGURE 1 (a) The sequence of Ab10–40 peptide
and the allocation of the b1 and b2 fibril b-strands.
(b) The ibuprofen molecule has three structural
moieties—the hydrophobic phenyl G1, and isobutyl
G2, and hydrophilic carboxylate G3 groups. Nap-
roxen has two polar moieties, the methoxy and
carboxylate groups (G2 and G3), linked to the
central hydrophobic naphthalene ring (G1). Carbon
and oxygen atoms are shown in gray and red. (c)
Incoming Ab10–40 peptides interacting with amyloid
fibril in ibuprofen solution. Four Ab peptides in
orange form the fibril fragment. Two incoming
peptides in red are bound to the fibril edge. Ibuprofen
molecules are in light gray/red. Fibril protofilament
consists of four in-registry parallel b-sheets formed
by the b1 and b2 strands and has two distinct
edges—concave (CV) and convex (CX). Due to
indentation of b2, the CV edge has a groove.
Ibuprofen Anti-Aggregation Effect 2663REMD simulations, we directly probe the anti-aggregation
effect of ibuprofen. Specifically, we compute the free energy
landscapes of Ab fibril growth in the presence of ibuprofen
ligands interacting with incoming Ab peptides and amyloid
fibril. The impact of ibuprofen binding on Ab fibril elongation
is revealed by a comparison with a water environment free
of ligands (26). In our simulations, we used the twofold
symmetry Ab10–40 fibril structure derived from solid-state
NMR experiments (10) (Fig. 1 c). Based on our results, we
suggest a rationale for the ibuprofen anti-aggregation effect,
and propose a few strategies for its enhancement.METHODS
Molecular dynamics simulations
Simulations of Ab peptides and ibuprofen (Fig. 1) were performed using the
CHARMM MD program (39) and united-atom force-field CHARMM19
coupled with the SASA implicit solvent model (40). Their description, appli-
cability, and testing can be found in our previous studies (41,42). In partic-
ular, we have shown that the CHARMM19þSASA force field accurately
reproduces the experimental distribution of chemical shifts for Ca and Cb
atoms in Ab monomers (42,43). Parameterization of ibuprofen (Fig. 1 b)
in the CHARMM19 force field has been reported by us earlier (34). Accord-
ing to our tests of the ibuprofen force-field parameters, the in silico distribu-
tion of internal dihedral angles in ibuprofen is consistent with the density
functional theory calculations and vibrational spectroscopy (34). Argumentsfor selecting the CHARMM19 force field and the SASA model are presented
in the Supporting Material.
The simulation system consists of six Ab10–40 peptides interacting with
Nibu ¼ 60 ibuprofen molecules (Fig. 1). Four peptides are constrained to
form a fibril fragment, whereas two unconstrained peptides are free to asso-
ciate or dissociate from the fibril. The concentration ratio of ibuprofen to Ab
peptides is 10:1, which is only slightly higher than that used in most experi-
ments (20,21). Further description of the simulation system is provided in Sup-
porting Material. In addition, three other Ab peptide systems were considered:
1. Hexamer consisting of the four-peptide fibril fragment and two incoming
peptides in water;
2. Four-peptide fibril fragment without incoming peptides in ibuprofen
solution;
3. Monomer in ibuprofen solution.
These systems were studied by us earlier (26,34). Throughout the article,
the peptides in orange in Fig. 1 c are referred to as ‘‘fibril’’, and the red
peptides are termed ‘‘incoming’’.
Replica exchange simulations
Conformational sampling was performed using REMD (36). In total,
24 replicas were distributed linearly in the temperature range from 330 to
560 K with the increment of 10 K. The exchanges were attempted every
20 ps between all neighboring replicas with the average acceptance rate of
24%. Fourteen REMD trajectories were produced, resulting in a cumulative
simulation time of 67 ms. Between replica exchanges, the system evolved
using NVT underdamped Langevin dynamics with the damping coefficient
g ¼ 0.15 ps1 and the integration step of 2 fs. Because the initial parts of
REMD trajectories are not equilibrated and must be excluded fromBiophysical Journal 98(11) 2662–2670
2664 Chang et al.thermodynamic analysis, the cumulative equilibrium simulation time is
reduced to tsimz 56 ms. The REMD trajectories were started with random
distributions of incoming peptides and ligands. The convergence of REMD
simulations and error analysis are presented in the Supporting Material.
Computation of structural probes
The interactions formed by Ab peptides and ibuprofen were probed by
computing the number of side-chain contacts and hydrogen bonds (HBs).
A side-chain contact occurs if the distance between the centers-of-mass of
side chains is <6.5 A˚. (This cutoff approximately corresponds to the onset
of hydration of side chains as the separation distance between them
increases.) Computation of contacts formed by ibuprofen is described in
the Supporting Material. The backbone HBs between peptide NH and CO
groups were assigned according to Kabsch and Sander (44). The same defi-
nition was applied to detect HBs between ibuprofen and peptide backbone
NH groups. Following our previous studies, we distinguished three classes
of HBs. The first includes any peptide-fibril HB, whereas the second and
third classes are restricted to the HBs involved in the formation of parallel
(antiparallel) b-sheets by incoming peptides on the fibril edge. These HBs
are termed parallel (pHB) and anti-parallel (aHB), respectively. Their
specific definitions are given in the Supporting Material. An incoming
peptide is bound if it forms at least one side-chain contact with the fibril.
Secondary structure in Ab peptides was computed using the distribution
of (f, j) backbone dihedral angles. Specific definitions of b-strand and helix
states can be found in our previous studies (42). Throughout the article,
angular brackets h. i imply thermodynamic averages. The distributions
of states produced by REMD were analyzed using a multiple histogram
method (45).RESULTS
Ibuprofen suppresses association of Ab peptides
with the ﬁbril
Binding of incoming Ab peptides to the fibril was probed by
computing the thermal averages of the number of hydro-
phobic contacts hCh(T)i, the number of HBs hNhb(T)i, and
the number of pHBs hNphb(T)i (see Methods). Fig. 2 showsFIGURE 2 Binding of Ab10–40 peptides to amyloid fibril is probed by the
thermal averages of the number of hydrophobic contacts hCh(T)i (thick
lines), the number of HBs hNhb(T)i (thin lines), and the number of parallel
HBs hNphb(T)i (dashed lines). The plots show that ibuprofen suppresses
Ab binding to the fibril. The data in solid and shaded representations are
obtained in ibuprofen solution and water, respectively.
Biophysical Journal 98(11) 2662–2670that, in ibuprofen solution, the number of peptide-fibril inter-
actions increases with the decrease in temperature T. Fig. 2,
which also displays the peptide-fibril interactions in water
(26), reveals that incoming peptides bind with higher affinity
to the fibril in the absence of ligands. To compare binding in
both environments, we selected the temperature T ¼ 360 K,
at which Ab peptide undergoes locking transition in water
(26). In ibuprofen solution, the numbers of peptide-fibril
hydrophobic contacts and HBs are hChiz 7.1 and hNhbiz
8.0, respectively. Approximately 60% of peptide-fibril HBs
are classified as parallel (hNphbi z 4.7 ¼ 0.6 hNhbi). At
the same temperature, the peptide-fibril interactions in water
are considerably stronger. For example, hChi is increased to
9.8, whereas the numbers of peptide-fibril HBs, hNhbi and
hNphbi, are z10.5 and 6.0. Therefore, due to ibuprofen,
these peptide-fibril interactions become 20–30% weaker
and the ligand appears to destabilize binding of Ab peptides
to the fibril.Ibuprofen binds to Ab species
To determine the cause of ibuprofen’s impact on fibril
growth, we studied the interactions of this ligand with Ab.
The inset to Fig. 3 shows the probability Pb(T) of ibuprofen
binding to Ab peptides in hexameric system as a function of
temperature. A monotonic increase in Pb(T) as temperature is
lowered implicates ibuprofen binding to Ab peptides withΔFb/RT
FIGURE 3 Free energy of ibuprofen ligand F(rb) as a function of the
distance rb between ligand and the surface of Ab hexamer at 360 K. The
free energy of binding DFb (Table 1) is obtained by integrating over the
bound states (shaded) with F(rb) % Fmin þ 1.0 RT, where Fmin is the free
energy minimum at small rb. The distance rb represents the minimal distance
between the ligand and Ab. The profile F(rb) indicates that binding to Ab is
thermodynamically preferred. The value of F at rb > 29 A˚ is set to zero.
(Inset) Probability Pb(T) of ibuprofen binding to Ab as a function of temper-
ature T (thick line). The probability Pbi(T) of ibuprofen binding to aggrega-
tion interface versus temperature (thin line). The dashed line marks the
probability value of 0.5. At T < Tbz 376 K ibuprofen-bound state is ther-
modynamically preferred (Pb> 0.5). Pb and Pbi are obtained by considering
contacts between ibuprofen and Ab side chains.
TABLE 1 Binding of ibuprofen to Ab species at 360 K
Ab species DFb/RT*
Monomery 3.8
Fibrily 5.6
Fibril þ incoming peptides 5.6
*The free energy of binding DFb is computed as described in the caption to
Fig. 3.
yBinding of ibuprofen to monomers and fibrils was studied in Raman et al.
(34). Here DFb/RT is recomputed at 360 K.
Ibuprofen Anti-Aggregation Effect 2665the binding midpoint occurring at Tb z 376 K (Pb(Tb) ¼
0.5). At 360 K, Pb z 0.63 and the number of bound
ligands is hLi z 38.0. The inset to Fig. 3 also displays the
probability Pbi(T) of ibuprofen binding to the aggregation
interface (i.e., of interacting simultaneously with the fibril
and incoming peptides). We found that Pbiz 0.2, implying
that approximately one-third (hLii z 11.7) of all bound
ligands are localized at the interface.
Further insight is provided by the binding free energy F(rb)
computed as a function of the distance between the ligand
and Ab surface rb. The free energy profile in Fig. 3 reveals
a single minimum at rb, 0z 5 A˚, and according to Table 1,
the ibuprofen binding free energy is DFb z 5.6 RT. The
computations of F(rb) separately for the fibril and incoming
peptides do not reveal substantial difference in DFb
(z 5.5 RT andz 5.3 RT, respectively). Therefore, there
is a strong thermodynamic preference for ibuprofen to bind to
Ab fibril and peptides, and we surmise that this factor desta-
bilizes peptide-fibril interactions.ΔFB-U /RT (W) 
a
ΔFB-U /RT (IBU) 
b
water ibuprofen 
M
L
L
D
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D
M
APImpact of ibuprofen on ﬁbril elongation
The changes in fibril growth induced by ibuprofen can be
probed by the free energy landscape of peptide binding. To
compare docking transitions in water and ibuprofen environ-
ments, we computed the free energy profiles F(C), where C
is the number of peptide-fibril side chain contacts. (Because
C measures any peptide-fibril interaction without regard to
fibril-like content, it is appropriate reaction coordinate for
docking.) Fig. 4 a shows that both F(C) plots feature a single
minimum, which is consistent with the barrierless nature
of binding of Ab peptides to amyloid fibril (26). More
importantly, with respect to water environment, ibuprofen
interactions increase the free energy of Ab bound state by
DDFB–U ¼ DFB–U(IBU) – DFB–U(W) z 2.5 RT (Table 2
and Fig. 4 a) and shift it to smaller C. However, the free
energy gain of Ab binding to the fibril in ibuprofen solution
(DFB–Uz7.4 RT) is still sufficient to ensure peptide dock-
ing to the fibril (Fig. 2).
The docking temperature Td is estimated from the temper-
ature dependence of the system free energy F(T). If docking
is a continuous transition, F(T) can be approximated by the
quadratic fitting function a(T – Td)2, where a is a constant
(46). The inset to Fig. 4 a shows that a good fit to F(T) at
T ( 450 K is obtained when a ¼ 0.019 kcal/(mol K2) and
Td ¼ 322 K. For comparison, in water, Td ¼ 380 K
(26)—implying that ibuprofen binding decreases the dock-
ing temperature by almost 60 K.
To examine the locking transition, we consider the two-
dimensional free energy landscape F(Nahb, Nphb), whereFIGURE 4 (a) Free energy of incoming Ab peptide F(C)
as a function of the number of peptide-fibril side-chain
contacts C in water (open circles, W) and in ibuprofen solu-
tion (solid circles, IBU). The free energy of Ab binding to
the fibril is DFB–U ¼ FB – FU, where FB and FU ¼ 0 are
the free energies of bound (B) and unbound (U, C ¼ 0)
states. FB is computed by integrating over the B states
(shaded) with F(C) % Fmin þ 1.0 RT, where Fmin is the
minimum in F(C). The plot shows that ibuprofen destabi-
lizes Ab binding to the fibril. (Inset) Temperature
dependence of the system free energy F(T) calculated self-
consistently from the multiple histogram method (45).
Quadratic fitting function, from which the docking temper-
ature Td is estimated, is shown by the solid continuous
curve. Maximum value of F(T) is set to zero. (b) Free energy
surfaces F(Nahb, Nphb) for bound Ab peptide as a function of
the number of antiparallel HBs Nahb and parallel HBs Nphb
formed between the peptide and the fibril. The locked (L),
antiparallel (AP), docked (D), and mixed (M) states are
marked. The free energy landscapes show that, due to
ibuprofen, the L state becomes less stable with respect to
state D. Panels a and b are computed at 360 K.
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TABLE 2 Binding of incoming Ab peptides to amyloid ﬁbril at
360 K
Environment DFB–U/RT* DFL–D/RT
y DF0/RTz
Water 9.9 2.0 3.8
Ibuprofen 7.4 1.0 2.8
*DFB–U is the free energy difference between the bound and unbound states
(Fig. 4 a).
yDFL–D ¼ FL – FD is the free energy gap between the locked (L) and docked
(D) states (Fig. 4 b). The free energy of L states FL is obtained by integrating
the free energies F(0, Nphb> 0)% FL, min þ 1.0 RT, where FL, min is the free
energy minimum in the L state.
zDF0 is the free energy escape barrier for the L state.
2666 Chang et al.Nahb and Nphb are the numbers of antiparallel and parallel
HBs (see Methods). These structural probes measure the
formation of parallel and antiparallel b-sheets by incoming
peptides. In Fig. 4 b, four free energy basins can be identi-
fied: locked states featuring parallel b-sheets (L:Nphb > 0,
Nahb ¼ 0); the states with antiparallel b-sheets (AP:Nphb ¼
0, Nahb > 0); docked states (D:Nphb ¼ 0, Nahb ¼ 0); and
the states with mixed parallel and antiparallel b-sheet struc-
ture (M:Nphb> 0, Nahb > 0). There are significant changes in
the equilibrium distribution of bound states as L, AP, and M
states become less stable with respect to the D state. Indeed,
compared to water, the free energy gap DFL–D (Table 2) is
reduced by z1.0 RT in ibuprofen solution. The locking
temperature Tl can be obtained by using the probability of
occupancy of the L state, PL. Consistent with our previous
study (26), we operationally defined the L state as the confor-
mations with Nphb > 3 and Nahb ¼ 0. With this definition,
PL ¼ 0.5 at Tl z 330 K in ibuprofen solution. Because in
water Tlz 360 K (26), ibuprofen lowers the locking temper-
ature by 30 K. Note that ibuprofen also reduces the escape
free energy barriers for the L state (Table 2). Therefore,
ibuprofen destabilizes Ab locked states relative to disordered
docked states.
The distribution of peptide-fibril interactions is examined
using the thermally averaged map of backbone HBs
hNhb(i, j)i formed between the fibril residue i and the residue
j from incoming peptide. The HB maps hNhb(i, j)i shown in
Fig. 5 for ibuprofen solution and water display diagonal andwater ib
β1 β2 β1
β1
β2
β1
β2
Biophysical Journal 98(11) 2662–2670off-diagonal traces of peptide-fibrils interactions. Both HB
maps are qualitatively similar, but their analysis reveals
subtle changes induced by ligand binding. It follows
from Fig. 5 that in water, the number of HBs formed by
the b1 and b2 regions of incoming peptide, hNhb(b1)i and
hNhb(b2)i, are 4.6 and 4.5, respectively (26). In ibuprofen
solution, hNhb(b1)i and hNhb(b2)i are reduced to 3.9
(a 20% change) and 2.7 (a 40% change). Likewise, the
values of hNhb(b1)i and hNhb(b2)i computed for the fibril
peptides decrease from 6.7 and 3.2 in water to 5.0 (a 30%
change) and 2.6 (a 20% change) in ibuprofen solution. The
number of HBs formed between the b1 regions of incom-
ing peptide and the fibril hNhb(b1, b1)i (¼ 2.0) remains
unchanged upon ibuprofen binding, although there is a reduc-
tion in the number of HBs formed between other Ab regions.
For example, the largest decrease (by 40%) is observed in the
number of HBs formed between the fibril b1 and peptide
b2 regions (hNhb(b1, b2)i is reduced from 3.8 to 2.1). As
a result, the share of b1–b1 HBs increases from 20% in water
to 30% in ibuprofen solution. Because similar observations
follow from the analysis of peptide-fibril side-chain contacts,
the b1–b1 peptide-fibril interactions appear to be the least
affected by ibuprofen.
DISCUSSION
Free energy landscape of ﬁbril growth
in ibuprofen solution
We showed that ibuprofen binding weakens the interactions
between incoming Ab peptides and the fibril. To analyze
fibril elongation we utilized the free energy landscape
perspective, which has been useful in protein folding (47).
It follows from our results that, due to ibuprofen, the bound
state of Ab peptide becomes less stable (Table 2). Simulta-
neously, the free energy gap separating the locked and
docked states is reduced (Table 2). Consistent with the
changes in free energies, the number of peptide-fibril interac-
tions (HBs or side-chain contacts) is reduced by 20–40%
(Figs. 2 and 5). Furthermore, in ibuprofen solution, the
docking and locking peptide transitions occur at tempera-
tures that are 60 and 30 K lower than in water, respectively.uprofen 
β2
FIGURE 5 Thermally averaged maps
of backbone HBs hNhb(i, j)i formed
between the fibril residue i and the
residue j from incoming peptide. The
maps are computed at 360 K. The resi-
dues in the b1 and b2 Ab regions are
enclosed in boxes. Similarity in the
distribution of hNhb(i, j)i in both panels
suggests that ibuprofen does not qualita-
tively change the aggregation interface.
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free energies of Ab peptides and ibuprofen. In the previous
study, we have explored ibuprofen binding to Ab monomers
and fibril fragments (without incoming peptides) (34). Here
we recompute the binding free energiesDFb at 360 K (Table 1)
and compare them with the free energy of Ab binding DFB–U
(Table 2). Although ibuprofen binding to Ab fibrils is
preferred over interactions with the monomers, both DFb
values are at least 4.3 RT higher than DFB–U. Therefore, in
competing for fibril binding sites, Ab peptides have stronger
affinity than ibuprofen. Nevertheless, ibuprofen does reduce
the peptide binding free energy gain (DFB–U in Table 2) and
impedes or even stalls the increase in peptide-fibril interac-
tions at the temperatures below its binding midpoint Tb z
376 K (as seen in Fig. 2 for hNhb(T)i).
Taken together, our findings suggest that ibuprofen desta-
bilizes, but does not entirely block, Ab deposition onto the
amyloid fibril. Because all bound Ab states (locked and
docked) are destabilized (Fig. 4 a), ibuprofen is expected
to slow down fibril elongation.Molecular basis of ibuprofen anti-aggregation
effect
It has been shown in our previous study that ibuprofen
preferentially binds to the concave (CV) edge of Ab fibril
(Fig. 1 c and Fig. 5 in (34)). At 330 K the ratio of the numbers
of ligands bound to the CV and convex (CX) edges is ~2:1,
whereas at 360 K it becomes 1.4:1. The CV edge is also
a primary binding location for incoming Ab peptides (26).
For example, at 360 K the probability of CV binding, PCV,
exceeds that of the CX, PCX, as PCV:PCXz 9:1. The binding
of Ab or ibuprofen to the fibril fragment sides is negligible
(26,34). These observations suggest that ibuprofen and Ab
compete for the same binding location (the CV edge) on the
amyloid fibril. To illustrate this conclusion, we plot in
Fig. S2 the probabilities PCV and PCX as a function of temper-
ature in water and ibuprofen solution. At temperatures above
the ibuprofen binding midpoint (Tbz 376 K), PCV (and PCX)
are similar in both environments. However, at T ( Tb in
ibuprofen solution, PCV reverses monotonic increase and
declines to z0.8 at 360 K. Fig. S2 suggests that ibuprofen
reduces the difference in the fibril edge affinities for Ab.
Indeed, in water, the free energy of the CV edge Ab binding
is lower than that for the CX by DFCV–CX z 2.5RT (26).
In ibuprofen solution, DFCV–CX is reduced to 1.5 RT. Con-
sequently, ibuprofen anti-aggregation effect can be also
explained by the fact that a fraction of Ab peptides is forced
to bind to the low affinity CX edge.
To establish energetic factors controlling ligand binding,
we computed the average energy Einter of intermolecular
interaction and the average solvation energy Esolv per
ibuprofen molecule at 360 K. Upon binding Einter decreases
by DEinterz 12.5 kcal/mol (from 1.4 to 13.9 kcal/mol),
while Esolv increases by 1.0 kcal/mol. The van der Waals(vdW) interactions represent the main contribution to DEinter,
making up >90% of its value. Therefore, vdW interactions
appear to be the main driving factor in ligand binding.
This conclusion is supported by the changes in accessible
surface area (ASA) occurring upon ibuprofen binding
at 360 K. The average ASA values for the three groups
G1, G2, and G3 (Fig. 1 b) in unbound ibuprofen are
ASAu(G1) ¼ 90 A˚2, ASAu(G2) ¼ 161 A˚2, and ASAu(G3) ¼
153 A˚2, respectively. For bound ligands we obtained
ASAb(G1) ¼ 37 A˚2, ASAb(G2) ¼ 83 A˚2, and ASAb(G3) ¼
68 A˚2. Therefore, upon binding, the ASAs of these groups
are reduced by 53, 78, and 85 A˚2, respectively, or by 9,
20, and 17 A˚2, respectively, per atom. Assuming that the
extent of burial reflects the strength of binding interactions,
we conclude that G3 and G2 are the most important for
binding. Because the aromatic G1 is sandwiched between
G2 and G3, the geometric reasons might limit G1 participa-
tion in binding. Note that ibuprofen burial may result from
the interactions with the fibril and/or other bound ligands.
If one considers the changes in ASA that occur exclusively
from interactions with the fibril (i.e., by omitting neighboring
ligands), then the ASAs of ibuprofen groups are reduced by
27, 41, and 52 A˚2. Therefore, the relative importance of
ibuprofen groups for binding does not depend on the details
of ASA computations. Consistent with the dominant contri-
bution of vdW interactions, both hydrophilic G3 and hydro-
phobic G2 groups participate in ligand binding. Similar
observations have been made in our previous study that
ibuprofen-binding sites are composed of the mixture of
hydrophobic and hydrophilic residues (34).
Because polar G3 has somewhat higher binding affinity
than the hydrophobic G2 (in terms of ASA changes),
ibuprofen binding could be enhanced by G2 modifications,
possibly, by functionalizing it with polar atoms and creating
a structural motif with two polar atomic groups linked to the
central hydrophobic moiety (G1, Fig. 1 b). A similar motif is
present in the structure of naproxen (Fig. 1 b), which, consis-
tent with our proposal, binds more tightly to Ab fibrils than
ibuprofen (20). According to competition curves probing
the replacement of molecular imaging probe 18FFDDNP, the
concentration of ibuprofen must be at least twice larger than
that of naproxen to reduce the probe binding by one-half.
To test our proposal in silico, we performed REMD simu-
lations of 40 naproxen molecules coincubated with the fibril
fragment formed by four Ab10–40 peptides. In line with the
experiments, we found that naproxen binds with higher
affinity to the fibril than ibuprofen. For example, the binding
free energy of naproxen DFb is z 2.4 RT is lower than for
ibuprofen. Furthermore, the midpoint of naproxen binding
occurs at Tb ¼ 398 K, which is >30 K higher than Tb ¼
362 K for ibuprofen (34). The preliminary analysis of nap-
roxen appears to support our proposal concerning the
enhancement of ligand binding. However, further studies
are needed to evaluate the contribution of the hydrophobic
G1 naphthalene group.Biophysical Journal 98(11) 2662–2670
2668 Chang et al.An important implication of naproxen binding is that
ligand-fibril interactions appear to depend on the chemical
structure of the ligands. This conclusion is further supported
by the observation that ibuprofen binds with higher affinity
to the CV fibril edge by localizing in its groove (Fig. 1 c)
(34). The analysis of binding energetics reveals that this
binding preference stems from the formation of attractive
interligand interactions facilitated by the CV edge geometry.
It is possible that ligand-excluded volume also adds to the
anti-aggregation effect, but further studies are needed to
precisely assess the relative contributions of these factors.Ibuprofen does not change Ab aggregation
interface
Our data suggest that ibuprofen has no major impact on the
Ab aggregation interface involved in fibril growth. As in
water, the interface is polarized, because peptide-fibril inter-
actions preferentially involve the b1 Ab regions (41,48).
Although most peptide-fibril interactions are reduced by
20–40%, the b1-b1 interactions are largely unaffected by
ibuprofen. Therefore, ibuprofen further enhances the polari-
zation of aggregation interface. It is also instructive to
compute the average registry offsets for peptide-fibril pHBs
hR(i, j)i (see the Supporting Material). We found that in
water and in ibuprofen solution, hR(i, j)i remains almost
the same (z11). Thus, parallel b-sheets formed by incoming
peptides on the fibril edge are typically off-registry (hRi >>
1) in both environments.
It is possible that anti-aggregation effect of ibuprofen is due
to the changes in the Ab secondary structure induced by the
ligand. To explore this possibility, we computed the fractions
of b-strand hSi and helix hHi structure in Ab incoming
peptides in ibuprofen solution. Compared to water (26), a small
decrease in hSi is observed from 0.52 to 0.48. The fraction of
helix structure hH i remains unchanged within the margin of
error (0.12 vs. 0.11). Therefore, the impact of ibuprofen
binding on secondary structure of bound Ab peptides is small
and the peptides retain mostly b-strand conformations. Conse-
quently, the anti-aggregation effect of ibuprofen is unlikely to
be associated with the changes in Ab secondary structure. This
finding suggests that ibuprofen interferes directly with
peptide-fibril interactions as described above.
It is also interesting to consider the changes in the thickness
D of the layer formed by bound Ab on the fibril edge. Fig. S3
compares the temperature dependencies D(T) obtained in
ibuprofen solution and in water. We showed (26) that the
theory of polymer adsorption on attractive walls (49) appears
to be applicable to the binding of Ab peptides to amyloid fibril.
As a result similar to polymer adsorption, Ab binding is repre-
sented by the barrierless transition. Exploiting this analogy,
D(T) can be fit with the function D(T)x D0/(Tu  T) before
unbinding at Tu, where D0 is a constant (49). In water, a single
fitting function provides an adequate fit in the entire tempera-
ture range. In ibuprofen solution, D(T) requires superpositionBiophysical Journal 98(11) 2662–2670of two fitting functions with the crossover point at z440 K
(see the Supporting Material). This suggests that, due to
ibuprofen, two Ab binding regimes are observed. At high
temperatures well above the ibuprofen-binding midpoint,
Tb z 376 K, peptide-fibril interactions are not affected by
ibuprofen and the layer thicknessesD in water and in ibuprofen
solution are similar. At lower temperatures (T ( 440 K),
there is an onset of ibuprofen binding, and deposition of Ab
peptides is affected. As a result, the layer thickness D in
ibuprofen solution exceeds that in water by>1 A˚. The increase
inD signals swelling in the layer of peptides bound to the fibril
edge, which is consistent with the free energy analysis above.Comparison with experiments and simulations
Experimental studies have established an anti-aggregation
effect of ibuprofen. For example, ibuprofen reduces the
amount of Ab oligomers in mice brain tissues (18). In vitro
studies have found that ibuprofen partly inhibits Ab1–40 fibril
assembly in a concentration-dependent manner when coincu-
bated with fresh (i.e., not-fibrilized) Ab peptides (20,21).
Moreover, if the concentration ratio of ibuprofen to fibril
Ab is ~22 (which is higher than in our simulations), the ligand
completely blocks Ab1–40 fibril elongation (21). The study of
Thomas et al. (50) has used circular dichroism to investigate
the changes in secondary structure in preaggregated Ab25–35
peptides. They demonstrated that, at the ligand/peptide
concentration ratio of 8:1, ibuprofen reduces the b-structure
content roughly in half due to partial dissociation of the fibrils.
These experimental findings support our in silico results sug-
gesting that ibuprofen destabilizes peptide-fibril interactions
and the fibril-like locked state. However, we did not observe
dissociation of incoming peptides from the fibril induced
by ibuprofen as implied by some experimental findings
(20,21). The possible reasons for this discrepancy are as
follows. Compared to the temperatures used experimentally
(~300 K), our simulation results are obtained at a higher
temperature of 360 K, which is also close to the midpoint of
ibuprofen binding Tb z 376 K. Weakened ibuprofen-Ab
interactions together with the relatively low ibuprofen/Ab
ratio (compared to (21)) are likely to limit the anti-aggregation
action of this ligand in our study.
Experimental data implicates extension of amyloid fibrils
via monomer addition to their edges (37,38,51). If ibuprofen
affects fibril elongation, it is natural to expect that the
ligand binds to the edges of the fibril and directly interferes
with peptide-fibril interactions. This is also the conclusion
following from our study, which does not support indirect
anti-aggregation effect based on secondary structure changes
in Ab. Interestingly, direct interference with fibril formation
has been observed for tricyclic planar ligands (33). Using
MD simulations, Caflisch et al. (33) have studied 9,10-
anthraquinone binding to fibril-forming fragments Ab14–20.
Because this ligand destabilizes the formation of interstrand
HBs, it also reduces the accumulation of ordered aggregates.
Ibuprofen Anti-Aggregation Effect 2669It is interesting to speculate on the connection between
ibuprofen anti-aggregation effect and Ab mutations. In the
previous study, we showed that ibuprofen binding is mostly
driven by the geometry of Ab fibril surface and the ligands
tend to concentrate in the groove located on the CV fibril
edge (Fig. 1 c) (34). Here we further demonstrated that
vdW interactions appear to be the dominant binding factor.
If ibuprofen binding is not directly determined by Ab
sequence, then the anti-aggregation affect of ibuprofen
should be largely independent on Ab mutations—provided
they do not change the wild-type Ab fibril structure.
The important question to be addressed in future studies is
the impact of ibuprofen on the stability of Ab oligomers. We
have previously showed that, in contrast to fibril binding,
ibuprofen does not form large bound clusters when interact-
ing with Ab monomers (34). When extrapolated to oligo-
mers, these findings suggest that the mechanism of binding
to mobile relatively unstructured Ab species may be quite
different from the mechanism observed for the fibrils.CONCLUSIONS
Our study showed that binding of ibuprofen to Ab destabilizes
the interactions between incoming peptides and the amyloid
fibril. Ibuprofen binding changes the free energy landscape
of fibril growth and reduces the free energy gain of Ab peptide
binding to the fibril by x2.5 RT at 360 K. Furthermore,
ibuprofen interactions shift the thermodynamic equilibrium
from fibril-like locked states to disordered docked states.
We explain ibuprofen’s anti-aggregation effect by noting
that it competes with incoming Ab peptides for the same
binding site on the Ab fibril surface located on the concave
edge. Our simulations also suggest that ibuprofen does not
change the mechanism of fibril elongation or the secondary
structure of Ab peptides bound to the fibril. In summary,
our simulations offer plausible molecular basis for ibupro-
fen’s anti-aggregation effect known from experimental stu-
dies. The analysis of the energetics of ibuprofen binding can
be useful in designing new anti-aggregation agents.SUPPORTING MATERIAL
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